The list below provides the references to the research studies discussed in Learn About Tripping. The references are arranged according to the relevant section where the research is mentioned. Within each section, pertinent sentences are listed in the order they appear in the information sheet. Links to the studies are included if available online. Materials not available online may be accessed through your local library.
Why do we do it?
Approximately 17% of BC residents have tried hallucinogens:
Zhao, J., Vallance, K., Martin, G., Macdonald, S., & Stockwell, T. (2014). Prevalence of Substance Use in Lifetime, Past Year and Past 30 days in British Columbia and Other Provinces of Canada from 2008 to 2012(2). http://www.uvic.ca/research/centres/carbc/assets/docs/aod/gp-prevalence-report-cocaine-ecstasy-heroin.pdf
What happens when we are tripping?
Tripping can be a joyful and insightful or scary and stressful experience:
Studerus, E., Kometer, M., Hasler, F., & Vollenweider, F. X. (2011). Acute, subacute and long-term subjective effects of psilocybin in healthy humans: A pooled analysis of experimental studies. Journal of Psychopharmacology, 25(11), 1434–52.
Van Amsterdam, J., Opperhuizen, A., & van den Brink, W. (2011). Harm potential of magic mushroom use: A review. Regulatory Toxicology and Pharmacology, 59(3), 423–9.
Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008). The pharmacology of lysergic acid diethylamide: A review. CNS Neuroscience and Therapeutics, 14(4), 295–314.
Today there is renewed interest in such therapeutic uses that draw on the long association of these drugs with the pursuit of insight:
Smith, D. E., Raswyck, G. E., & Davidson, L. D. (2014). From Hofmann to the Haight Ashbury, and into the future: The past and potential of lysergic acid diethlyamide. Journal of Psychoactive Drugs, 46(1), 3–10.
Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008). The pharmacology of lysergic acid diethylamide: A review. CNS Neuroscience and Therapeutics, 14(4), 295–314.
About the author
The Canadian Institute for Substance Use Research, formerly CARBC, is a member of the BC Partners for Mental Health and Substance Use Information. The institute is dedicated to the study of substance use in support of community-wide efforts aimed at providing all people with access to healthier lives, whether using substances or not. For more, visit www.cisur.ca.
